NDC product
ANASCORP
NDC 66621-0150 · Rare Disease Therapeutics, Inc
Key facts
| Product NDC | 66621-0150 |
|---|---|
| Proprietary name | ANASCORP |
| Nonproprietary name | centruroides (scorpion) immune F(ab)2 (equine) |
| Substances | CENTRUROIDES FAB2 ANTIVENIN (EQUINE) |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAVENOUS |
| Labeler | Rare Disease Therapeutics, Inc |
| Product type | PLASMA DERIVATIVE |
| Marketing category | BLA |
| Application number | BLA125335 |
| Pharmacologic classes | Antivenin [EPC], Antivenins [CS], Passively Acquired Immunity [PE], Venom Neutralization [MoA] |
| Marketing start | Aug 3, 2011 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: